Orbicular, Apotex receive tentative USFDA approval for generic Ozempic
Orbicular and Apotex received tentative U.S. FDA approval for a generic Ozempic semaglutide injection. Apotex will commercialize the product in the United States as the ANDA applicant.
Orbicular Pharmaceutical Technologies said its generic version of Ozempic (semaglutide injection), developed in partnership with Apotex, has received Tentative Approval from the U.S. FDA. Apotex will commercialize the product in the United States as the ANDA applicant.
The company said the tentative approval marks a significant advance in expanding access to affordable semaglutide therapies. It also described the decision as particularly significant given the scientific and regulatory complexity of peptide-based generics, where demonstrating technical equivalence requires advanced analytical characterization, precise process control, and robust regulatory documentation.
Orbicular said achieving technical equivalence for complex peptide products requires deep scientific rigor, advanced analytical precision, and a highly disciplined development approach. Apotex said Orbicular’s scientific depth and commitment to quality were instrumental in supporting this complex program.
Orbicular is a Hyderabad-based developer of complex peptide-based generics. The product will be marketed and commercialised in the United States by Apotex Corp.